Rob Perez

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.

Life Science Cares is a collective effort of the life science industry to help address the impact of poverty on our neighbors in the greater Bay Area. Life Science Cares started in Boston in 2017 and expanded to Philadelphia in 2019, San Diego in 2020 and the Bay Area in 2021. Through uniting the human and financial resources of life science companies and industry leaders, we support nonprofit organizations that do the best work in fighting poverty and providing educational opportunity in our community. We work with organizations doing work in the areas of basic human survival (hunger, homelessness, domestic abuse, crime prevention, etc.), education (STEM education, college preparation and college success, educational enrichment and inspiration, etc.) and sustainability (job creation, job training, mentoring, and economic development.) Learn more at www.lscphilly.org

Our Company: Novel Treatments for Neuromuscular Disorders. Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated human efficacy related to muscle cramping. Novel Treatments for Neuromuscular Disorders, including Muscle Cramps. There is currently no proven or effective product for muscle cramps and spasms. Most muscle cramps are not caused by dehydration, lactic acid, electrolyte imbalance, or muscle tightness. That is why popular remedies like sports drinks, bananas, magnesium tablets, and stretching are usually ineffective. New research has shown that cramps and spasms do not originate in the muscle itself, but are caused instead by a neural mechanism: excessive firing of the motor neurons in the spinal cord that control muscle contraction. Flex Pharma is developing products to address muscle cramps and spasms by halting repetitive firing of the motor neurons. Our founders include professors from Harvard Medical School and Rockefeller University (Nobel prize, 2003). Preliminary testing of Flex Pharma’s product in humans has shown that it can relieve electrically induced muscle cramps in minutes, and the effect lasts for hours.

Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. The company has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and other rare and serious forms of obesity. Zafgen is well-capitalized and has assembled a team accomplished in bringing therapies to patients affected by metabolic disease.

Cidara (NASDAQ: CDTX) is developing long-acting therapeutics to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California.

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.

Life Science Cares is a collective effort of the life science industry to help address the impact of poverty on our neighbors in the greater Bay Area. Life Science Cares started in Boston in 2017 and expanded to Philadelphia in 2019, San Diego in 2020 and the Bay Area in 2021. Through uniting the human and financial resources of life science companies and industry leaders, we support nonprofit organizations that do the best work in fighting poverty and providing educational opportunity in our community. We work with organizations doing work in the areas of basic human survival (hunger, homelessness, domestic abuse, crime prevention, etc.), education (STEM education, college preparation and college success, educational enrichment and inspiration, etc.) and sustainability (job creation, job training, mentoring, and economic development.) Learn more at www.lscphilly.org

General Atlantic is a leading global investor with more than four and a half decades of experience providing capital and strategic support to over 830 companies throughout its history. Established in 1980, General Atlantic continues to be a dedicated partner to visionary founders and investors seeking to build dynamic businesses and create long-term value. The firm leverages its patient capital, operational expertise, and global platform to support a diversified investment platform spanning Growth Equity, Credit, Climate, and Sustainable Infrastructure strategies. General Atlantic manages approximately $108 billion in assets under management, inclusive of all strategies, as of March 31, 2025, with more than 900 professionals in 20 countries across five regions. For more information on General Atlantic, please visit: www.generalatlantic.com.

Life Science Cares (LSC) is a collective effort of the life science industry connecting companies with nonprofits that improve the lives of people living in poverty in Greater Boston, Philadelphia, San Diego, New York & San Francisco. In Boston, LSC harnesses the sector’s human and financial resources from companies and supports a portfolio of 25 nonprofit organizations. LSC’s partner organizations work to address basic survival needs like food and shelter, improve education, and develop job skills that increase long term economic sustainability for the community’s most vulnerable neighbors. For more information, visit: www.lifesciencecares.org. Check out our affiliates Life Science Cares Philadelphia, Life Science Cares San Diego, Life Science Cares New York & Life Science Cares Bay Area!

Our Company: Novel Treatments for Neuromuscular Disorders. Flex Pharma is a biopharmaceutical company dedicated to creating innovative, novel treatments for neuromuscular disorders, and has demonstrated human efficacy related to muscle cramping. Novel Treatments for Neuromuscular Disorders, including Muscle Cramps. There is currently no proven or effective product for muscle cramps and spasms. Most muscle cramps are not caused by dehydration, lactic acid, electrolyte imbalance, or muscle tightness. That is why popular remedies like sports drinks, bananas, magnesium tablets, and stretching are usually ineffective. New research has shown that cramps and spasms do not originate in the muscle itself, but are caused instead by a neural mechanism: excessive firing of the motor neurons in the spinal cord that control muscle contraction. Flex Pharma is developing products to address muscle cramps and spasms by halting repetitive firing of the motor neurons. Our founders include professors from Harvard Medical School and Rockefeller University (Nobel prize, 2003). Preliminary testing of Flex Pharma’s product in humans has shown that it can relieve electrically induced muscle cramps in minutes, and the effect lasts for hours.